Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease

Yasmine M. Kanaan, Brante P. Sampey, Desta Beyene, Ashwini K. Esnakula, Tammey J. Naab, Luisel J. Ricks-Santi, Sylvia Dasi, Agnes Day, Kwesi W. Blackman, Wayne Frederick, Robert L. Copeland, Edward Gabrielson, Robert L. Dewitty

Research output: Contribution to journalArticle

Abstract

Expression of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) can subdivide breast carcinomas into clinically meaningful classes. Cancers lacking expression of all three of these receptors (triple-negative breast cancer; TNBC) is of particular interest for molecular research because these tumors currently have no effective targets for therapy. Furthermore, TNBCs are relatively more prevalent among African-American women and can account for some of the health disparities associated with breast cancer. We approached a molecular understanding of how TNBC differs from ER+ breast cancer through a comprehensive gas chromatography (GC)-mass spectrometry (MS) and liquid chromatography (LC)/MS/MS-based and unbiased metabolomic analysis of a series of breast carcinomas from African-American patients. Remarkably, global metabolomic profiling of tumor tissues identified a total of 418 distinct metabolites, out of which 133 (31.8%) were shown to differ between the ER+ and TNBC tumors with statistical probability of p+ tumors. Additionally, biochemicals associated with increased proliferation, redox balance and the recently proposed oncometabolites, sarcosine and 2-hydroxyglutarate, were also detected at higher levels in the TNBC versus ER+ tumors. These studies demonstrate that TNBC tumors have metabolic signatures that distinguish them from ER+ tumors and suggest that distinctive metabolic characteristics of these tumors might offer new targets for treatment.

Original languageEnglish (US)
Pages (from-to)279-294
Number of pages16
JournalCancer Genomics and Proteomics
Volume11
Issue number6
StatePublished - Nov 1 2014

Fingerprint

Triple Negative Breast Neoplasms
Metabolome
Biomarkers
African Americans
Tumors
Estrogen Receptors
Neoplasms
Mass spectrometry
Breast Neoplasms
Metabolomics
Sarcosine
Liquid chromatography
Progesterone Receptors
Metabolites
Gas chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Gas Chromatography-Mass Spectrometry
Oxidation-Reduction
Health

Keywords

  • African-American women
  • Metabolomic
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Biochemistry

Cite this

Kanaan, Y. M., Sampey, B. P., Beyene, D., Esnakula, A. K., Naab, T. J., Ricks-Santi, L. J., ... Dewitty, R. L. (2014). Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics and Proteomics, 11(6), 279-294.

Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. / Kanaan, Yasmine M.; Sampey, Brante P.; Beyene, Desta; Esnakula, Ashwini K.; Naab, Tammey J.; Ricks-Santi, Luisel J.; Dasi, Sylvia; Day, Agnes; Blackman, Kwesi W.; Frederick, Wayne; Copeland, Robert L.; Gabrielson, Edward; Dewitty, Robert L.

In: Cancer Genomics and Proteomics, Vol. 11, No. 6, 01.11.2014, p. 279-294.

Research output: Contribution to journalArticle

Kanaan, YM, Sampey, BP, Beyene, D, Esnakula, AK, Naab, TJ, Ricks-Santi, LJ, Dasi, S, Day, A, Blackman, KW, Frederick, W, Copeland, RL, Gabrielson, E & Dewitty, RL 2014, 'Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease', Cancer Genomics and Proteomics, vol. 11, no. 6, pp. 279-294.
Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ et al. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics and Proteomics. 2014 Nov 1;11(6):279-294.
Kanaan, Yasmine M. ; Sampey, Brante P. ; Beyene, Desta ; Esnakula, Ashwini K. ; Naab, Tammey J. ; Ricks-Santi, Luisel J. ; Dasi, Sylvia ; Day, Agnes ; Blackman, Kwesi W. ; Frederick, Wayne ; Copeland, Robert L. ; Gabrielson, Edward ; Dewitty, Robert L. / Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. In: Cancer Genomics and Proteomics. 2014 ; Vol. 11, No. 6. pp. 279-294.
@article{e1535f7033f64164ae015672dfb1479b,
title = "Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease",
abstract = "Expression of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) can subdivide breast carcinomas into clinically meaningful classes. Cancers lacking expression of all three of these receptors (triple-negative breast cancer; TNBC) is of particular interest for molecular research because these tumors currently have no effective targets for therapy. Furthermore, TNBCs are relatively more prevalent among African-American women and can account for some of the health disparities associated with breast cancer. We approached a molecular understanding of how TNBC differs from ER+ breast cancer through a comprehensive gas chromatography (GC)-mass spectrometry (MS) and liquid chromatography (LC)/MS/MS-based and unbiased metabolomic analysis of a series of breast carcinomas from African-American patients. Remarkably, global metabolomic profiling of tumor tissues identified a total of 418 distinct metabolites, out of which 133 (31.8{\%}) were shown to differ between the ER+ and TNBC tumors with statistical probability of p+ tumors. Additionally, biochemicals associated with increased proliferation, redox balance and the recently proposed oncometabolites, sarcosine and 2-hydroxyglutarate, were also detected at higher levels in the TNBC versus ER+ tumors. These studies demonstrate that TNBC tumors have metabolic signatures that distinguish them from ER+ tumors and suggest that distinctive metabolic characteristics of these tumors might offer new targets for treatment.",
keywords = "African-American women, Metabolomic, Triple-negative breast cancer",
author = "Kanaan, {Yasmine M.} and Sampey, {Brante P.} and Desta Beyene and Esnakula, {Ashwini K.} and Naab, {Tammey J.} and Ricks-Santi, {Luisel J.} and Sylvia Dasi and Agnes Day and Blackman, {Kwesi W.} and Wayne Frederick and Copeland, {Robert L.} and Edward Gabrielson and Dewitty, {Robert L.}",
year = "2014",
month = "11",
day = "1",
language = "English (US)",
volume = "11",
pages = "279--294",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease

AU - Kanaan, Yasmine M.

AU - Sampey, Brante P.

AU - Beyene, Desta

AU - Esnakula, Ashwini K.

AU - Naab, Tammey J.

AU - Ricks-Santi, Luisel J.

AU - Dasi, Sylvia

AU - Day, Agnes

AU - Blackman, Kwesi W.

AU - Frederick, Wayne

AU - Copeland, Robert L.

AU - Gabrielson, Edward

AU - Dewitty, Robert L.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Expression of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) can subdivide breast carcinomas into clinically meaningful classes. Cancers lacking expression of all three of these receptors (triple-negative breast cancer; TNBC) is of particular interest for molecular research because these tumors currently have no effective targets for therapy. Furthermore, TNBCs are relatively more prevalent among African-American women and can account for some of the health disparities associated with breast cancer. We approached a molecular understanding of how TNBC differs from ER+ breast cancer through a comprehensive gas chromatography (GC)-mass spectrometry (MS) and liquid chromatography (LC)/MS/MS-based and unbiased metabolomic analysis of a series of breast carcinomas from African-American patients. Remarkably, global metabolomic profiling of tumor tissues identified a total of 418 distinct metabolites, out of which 133 (31.8%) were shown to differ between the ER+ and TNBC tumors with statistical probability of p+ tumors. Additionally, biochemicals associated with increased proliferation, redox balance and the recently proposed oncometabolites, sarcosine and 2-hydroxyglutarate, were also detected at higher levels in the TNBC versus ER+ tumors. These studies demonstrate that TNBC tumors have metabolic signatures that distinguish them from ER+ tumors and suggest that distinctive metabolic characteristics of these tumors might offer new targets for treatment.

AB - Expression of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) can subdivide breast carcinomas into clinically meaningful classes. Cancers lacking expression of all three of these receptors (triple-negative breast cancer; TNBC) is of particular interest for molecular research because these tumors currently have no effective targets for therapy. Furthermore, TNBCs are relatively more prevalent among African-American women and can account for some of the health disparities associated with breast cancer. We approached a molecular understanding of how TNBC differs from ER+ breast cancer through a comprehensive gas chromatography (GC)-mass spectrometry (MS) and liquid chromatography (LC)/MS/MS-based and unbiased metabolomic analysis of a series of breast carcinomas from African-American patients. Remarkably, global metabolomic profiling of tumor tissues identified a total of 418 distinct metabolites, out of which 133 (31.8%) were shown to differ between the ER+ and TNBC tumors with statistical probability of p+ tumors. Additionally, biochemicals associated with increased proliferation, redox balance and the recently proposed oncometabolites, sarcosine and 2-hydroxyglutarate, were also detected at higher levels in the TNBC versus ER+ tumors. These studies demonstrate that TNBC tumors have metabolic signatures that distinguish them from ER+ tumors and suggest that distinctive metabolic characteristics of these tumors might offer new targets for treatment.

KW - African-American women

KW - Metabolomic

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84912139595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912139595&partnerID=8YFLogxK

M3 - Article

C2 - 25422359

AN - SCOPUS:84912139595

VL - 11

SP - 279

EP - 294

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 6

ER -